Influence of previous corticosteroid treatment on the efficacy and safety of infliximab therapy in Crohn disease.

Authors:
Ailing Liu
Ailing Liu
National Institute for Nutrition and Food Safety
China
Yue Li
Yue Li
College of Life Sciences
Provo | United States
Hong Yang
Hong Yang
First Affiliated Hospital of Guangxi Medical University
China
Hong Lv
Hong Lv
Dalian University of Technology
China
Jiaming Qian
Jiaming Qian
Peking Union Medical College Hospital
China

Medicine (Baltimore) 2019 Apr;98(15):e15189

Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

To determine the effect of prior corticosteroid treatment on the results of infliximab (IFX) therapy in patients with Crohn disease (CD).Patients with CD treated with at least 3 IFX infusions between March 2009 and April 2017 were divided into steroid group (n = 43) and nonsteroid group (n = 22) and analyzed retrospectively.The cumulative probabilities of clinical remission and response to IFX at weeks 14, 30, 54, and 78 were higher in the steroid group, though this difference was not statistical significant. At the mean interval of 11.7 months following the initiation of IFX treatment, the mucosal healing rate was significantly higher in the steroid group (71.0% vs 22.2%, P < .01). There was no statistical difference in the incidence of adverse reactions between the 2 groups.In CD, patients with prior corticosteroid treatment may increase the response rate to IFX therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485721PMC
April 2019
9 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 24, 2019, 12:39 am EST

Publication Analysis

Top Keywords

steroid group
12
crohn disease
8
corticosteroid treatment
8
higher steroid
8
retrospectivelythe cumulative
4
analyzed retrospectivelythe
4
n = 22 analyzed
4
cumulative probabilities
4
probabilities clinical
4
remission response
4
clinical remission
4
group n = 22
4
nonsteroid group
4
2017 divided
4
april 2017
4
2009 april
4
divided steroid
4
group
4
n = 43 nonsteroid
4
222% p 
4

Similar Publications